Repurposing Antimalarials to Tackle the COVID-19 Pandemic

Artemisinin-based combination therapies (ACTs) have demonstrated in vitro inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Artemisinins have also shown anti-inflammatory effects, including inhibition of interleukin-6 (IL-6) that plays a key role in the development of sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishna, Sanjeev, Augustin, Yolanda, Wang, Jigang, Xu, Chengchao, Staines, Henry M., Platteeuw, Hans, Kamarulzaman, Adeeba, Sall, Amadou, Kremsner, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2021
Materias:
Forum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572038/
https://www.ncbi.nlm.nih.gov/pubmed/33153922
http://dx.doi.org/10.1016/j.pt.2020.10.003
Descripción
Sumario:Artemisinin-based combination therapies (ACTs) have demonstrated in vitro inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Artemisinins have also shown anti-inflammatory effects, including inhibition of interleukin-6 (IL-6) that plays a key role in the development of severe coronavirus disease 2019 (COVID-19). There is now sufficient evidence for the effectiveness of ACTs, and in particular artesunate/pyronaridine, to support clinical studies for COVID-19 infections.

Ejemplares similares